지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.7
- 수록면
- 765 - 773 (9page)
- DOI
- 10.4143/crt.2023.1294
이용수
초록· 키워드
오류제보하기
Purpose There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)–based circulating tumor DNA (ctDNA) assay.
Materials and Methods Analytical validation was conducted in vitro by evaluating the limit of detection (LOD), precision, and specificity for various genomic aberrations. The real-world performance in non–small cell lung cancer (NSCLC) was assessed by comparing the results of AlphaLiquid100 to the tissue-based results.
Results The LODs with 30 ng input DNA were 0.11%, 0.11%, 0.06%, 0.21%, and 2.13 copies for detecting single nucleotide variants, insertions, deletions, fusions, and copy number alterations (CNA), respectively. Quantitatively, single nucleotide variants/insertions and deletions, fusions, and CNAs showed a good correlation (R2=0.91, 0.40, and 0.65; y=0.95, 1.06, and 1.19) to the manufacturer’s values, and per-base specificities for all types of variants were near 100%. In real-world NSCLC (n=122), key actionable mutations in NSCLC were detected in 60.7% (74/122) with the ctDNA assay. Comparative analysis against the NGS-based tissue results for all key mutations showed positive percent agreement (PPA) of 85.3%. For individual genes, the PPA was as high as 95.7% for epidermal growth factor receptor (EGFR) mutations and 83.3% for ALK translocations. AlphaLiquid100 detected drug-sensitive EGFR mutation at a variant allele frequency as low as 0.02% and also identified an EGFR mutation in a case where tissue sample missed. Blood samples collected post-targeted therapies revealed additional acquired mutations.
Conclusion The AlphaLiquid100 ctDNA assay demonstrates robust analytical validity, offering clinically important information for NSCLC patients.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cancer Research and Treatment
2019 .01
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Cancer Research and Treatment
2024 .07
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non?small cell lung carcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
-
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
Journal of Korean Medical Science
2016 .01
-
EGFR 돌연변이와 ALK 재배열 공존하는 폐선암 환자 1예
대한내과학회지
2016 .01
-
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment
2023 .04
-
Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
최근 본 자료
댓글(0)
0